Psychiatry and Neurology, Neurology · Fairfax, VA
NPI
1235108986
Since 2006
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
3020 Hamaker Ct, Suite 400
Fairfax, VA, 22031
Phone (703) 876-0800
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.2M
104,556 services
Medicare patients, 2024
638
Average age 74
Drug cost, 2024
$2.3M
1,512 prescriptions
Company payments, 2025
$6,538
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by James P Simsarian was code J2350 (injection, ocrelizumab, 1 mg), 84,000 times for 81 patients. In total James P Simsarian billed 104,556 services in 49 codes, and Medicare paid $4.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-06-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J2350 Injection, ocrelizumab, 1 mg | Office | 84,000 | 81 | $44.21 | $3.7M |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 4,350 | 66 | $0.22 | $978 |
| 99214 Office E&M - Established | Office | 539 | 315 | $101.79 | $55K |
| 93880 Duplex Scan - Extracranial Arteries | Office | 246 | 234 | $165.53 | $41K |
| 99215 Office E&M - Established | Office | 205 | 140 | $133.49 | $27K |
| 96413 Chemotherapy Administration | Office | 205 | 94 | $108.89 | $22K |
| 96415 Chemotherapy Administration | Office | 194 | 88 | $23.86 | $4,629 |
| 96365 Intravenous Infusion, Hydration | Office | 171 | 89 | $54.47 | $9,315 |
| 99213 Office E&M - Established | Office | 158 | 91 | $67.49 | $11K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 155 | 115 | $14.07 | $2,180 |
| 96374 Injection Administration | Office | 146 | 81 | $31.38 | $4,581 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 120 | 68 | $0.61 | $73.77 |
| 96375 Injection Administration | Office | 110 | 62 | $13.16 | $1,448 |
| 99212 Office E&M - Established | Office | 102 | 67 | $37.13 | $3,788 |
| 93040 Electrocardiogram | Office | 89 | 84 | $11.27 | $1,003 |
By year: 2022 $4.1M for 95,706 services; 2023 $4.0M for 94,736 services; 2024 $4.2M for 104,556 services.
Medicare prescription drug claims, 2024
In 2024, the drug James P Simsarian prescribed most often to Medicare patients was Gabapentin, with 122 prescriptions and refills. In total James P Simsarian wrote 1,512 Medicare prescriptions that cost $2.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 122 | 273 | 45 | $2,605 |
| Baclofen Generic | 110 | 276 | 38 | $3,469 |
| Pregabalin Generic | 60 | 106 | 18 | $2,978 |
| Donepezil Hcl Generic | 55 | 144 | 19 | $969 |
| Kesimpta Pen Ofatumumab | 46 | 70 | Under 11 | $665K |
| Teriflunomide Generic | 44 | 44 | Under 11 | $3,768 |
| Dalfampridine Er Dalfampridine | 41 | 67 | Under 11 | $17K |
| Levetiracetam Generic | 37 | 105 | 11 | $1,225 |
| Fluoxetine Hcl Generic | 28 | 70 | Under 11 | $567 |
| Duloxetine Hcl Generic | 28 | 76 | Under 11 | $1,104 |
| Betaseron Interferon Beta-1b | 28 | 35 | Under 11 | $346K |
| Sumatriptan Succinate Generic | 25 | 41 | Under 11 | $264 |
| Tizanidine Hcl Generic | 25 | 73 | Under 11 | $1,057 |
| Propranolol Hcl Generic | 25 | 66 | Under 11 | $488 |
| Tolterodine Tartrate Er Tolterodine Tartrate | 24 | 67 | Under 11 | $3,489 |
Brand drugs: 249 claims; generic drugs: 1,246 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid James P Simsarian $6,538 ($6,538 in general payments such as food, travel and fees) from 9 companies. The largest payer was Genentech USA, Inc. with $6,168.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.